The Dexcom Stelo, an over-the-counter continuous glucose monitor (CGM), offers a user-friendly and affordable option for diabetes management. While praised for its accessibility and informative app, it lacks certain advanced features of the Dexcom G7, such as higher glucose reading limits and customizable target ranges, making it less suitable for users with complex diabetes needs. However, the convenience and price point of the Stelo make it a valuable tool for many individuals.
Trinity Biotech (TRIB) has made significant progress in its continuous glucose monitor (CGM) technology. The company recently received a European patent for a process that enhances the performance of its glucose biosensor, leading to faster and more accurate glucose readings. This development, coupled with the growing CGM market, positions Trinity Biotech for future success.
Dexcom, a leading manufacturer of continuous glucose monitoring systems (CGMs), has announced a new feature for its Dexcom G7 CGM that allows users to send their real-time blood sugar levels to their Apple Watch, even when their iPhone is not nearby. This new feature, called Direct to Apple Watch, is made possible thanks to the dedicated Bluetooth connection on the Dexcom G7 CGM System. It will now send glucose information, as well as personalized alerts, directly to the user’s Apple Watch.
Previously, the Dexcom G7 had a companion Apple Watch app with a watch face complication. However, this app complication had a three-hour delay on synced data showing up. With Direct to Apple Watch, users will now get real-time readings and alerts right on the Apple Watch itself.
Dexcom G7 users will still need an iPhone to set it up with their Apple Watch, and the iOS Health app is still a requirement to view the blood glucose data and other metrics captured with the Apple Watch. To get the Direct to Apple Watch feature on your Dexcom G7, you have to be in the U.S., U.K., and Ireland. More markets will get the feature later this month.
